Monoamine Oxidase (MAO) Inhibitors in Psychiatric Therapy
Iproniazid and several other hydrazine inhibitors of the oxidative deamination of brain catecholamines and indoleamines were the first drugs shown to be effective in the treatment of major depressive disorders. Although iproniazid itself proved to be hepatotoxic and is no longer used clinically, and the tricyclic antidepressants came to be regarded as safer and more broadly effective drugs, other monoamine oxidase (MAO) inhibitors continue to be widely used, especially in tricyclicresistant depressed patients.
- Beckmann H, Riederer P, eds (1983): Monoamine Oxidase and Its Selective Inhibitors: New Concepts in Therapy and Research. Basel: KargerGoogle Scholar
- Murphy DL, Garrick NA, Cohen RM (1983): Monoamine oxidase inhibitors and monoamine oxidase: Biochemical and physiological aspects relevant to human psychopharmacology. In: Drugs in Psychiatry, Vol 1, Antidepressants, Burrows JD, Norman TR, Davies E, eds. Amsterdam: Elsevier/North Holland Biomedical PressGoogle Scholar
- Squires RF (1978): Monoamine oxidase inhibitors: Animal pharmacology. In: Handbook of Psychopharmacology, Vol 14, Iverson LL, Iversen SD, Snyder SH, eds. New York: Plenum PressGoogle Scholar
- Tipton KF, Dostert P, Strolin Benedetti M, eds (1984): Monoamine Oxidase and Disease. London: Academic PressGoogle Scholar